Hi, my name is Monty Mythen. I'm from University College London in England. I just gave a talk on the engineering of next-generation resuscitation fluids—what we might call "superfluids"—and what the future holds in fluid development.

My key conclusions are that, over the next decade, most advances in resuscitation fluids will likely come from semi-synthetic products. These will be improved, modified, and reformulated to better match physiological pH and electrolyte compositions, making them safer and more effective.

Looking further ahead, we must continue to pursue the development of so-called "shelf blood"—a synthetic or engineered blood substitute. While this remains an unrealized goal, it's a critical frontier in fluid therapy, and one we must not abandon.